References

M
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39-S45.
Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the directacting antiviral era: an economic evaluation. J Hepatol. 2016;65(1):17-25.
Martinello M, Orkin C, Cooke G, et al. Short-duration pan-genotypic therapy with glecaprevir/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020;72(1):7-18.
Maruschak L, Chari KA, Simon AE, DeFrances CJ. National survey of prison health care: selected findings. Natl Health Stat Report. 2016;(96):1-23.
Mast EE, Hwang L-Y, Seto DSY, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880-1889.
Mateu-Gelabert P, Sabounchi NS, Guarino H, et al. Hepatitis C virus risk among young people who inject drugs. Frontiers in Public Health. 2022;10:835836. doi:10.3389/fpubh.2022.835836.
Matheï C, Bourgeois S, Blach S, et al. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79(2):227-232.
Matsuda T, McCombs JS, Tonnu-MiHara I, McGinnis J, Fox DS. The impact of delayed hepatitis C viral load suppression on patient risk: historical evidence from the Veterans Administration. Forum Health Econ Policy. 2016;19(2):333-351.
Matthews GV, Hellard M, Kaldor J, Lloyd A, Dore GJ. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. AIDS. 2007;21(15):2112 - 2113.
Matthews GV, Bhagani S, Van der Valk M, et al. Sofosbuvir/velpatasvir for 12 vs 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;S0168-8278(21):00336-6.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.
Maurer K, Gondles EF, Efeti D, Strom HV, Strom HV. Hepatitis C in correctional settings: challenges and opportunities. 2015.
Mazzaro C, Little D, Pozzato G. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(26):2168-2170.
McCombs JS, Tonnu-MiHara I, Matsuda T, McGinnis J, Fox S. Can hepatitis C treatment be safely delayed? Evidence from the Veterans Administration healthcare system [PIN104]. Value Health. 2015;18(3):A245.
McGovern BH, Birch CE, Bowen MJ, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49(7):1051-1060.
McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57(4):1325-1332.
McLean RC, Reese PP, Acker M, et al. Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial. Am J Transplant. 2019;19(9):2533-2542.
Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20(18):2361-2369.
Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133(8):592-599.
Top